Pegylated liposomal doxorubicin (CAELYX®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines

Journal of Chemotherapy

Volumn 23, Issue 3, 2011, Pages 158-162

  Livi, L ^a   Meattini, I ^a   Scotti, V ^a   de Luca Cardillo, C ^a   Galardi, A ^a   Iermano, C ^a   Sanchez, L ^a   Nori, J ^a   Mangoni, M ^a   Franzese, C ^a   Orzalesi, L ^a   Bertocci, S ^a   Agresti, B ^a   Masoni, T ^a   Bianchi, S ^a   Cataliotti, L ^a   Biti, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anthracyclines; CAELYX ; Cardiac toxicity; Metastatic breast cancer; Pegylated liposomal doxorubicin

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANDIDIASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; ONCOGENE C ERB; STOMATITIS; THERAPY DELAY; THROMBOCYTE; THROMBOSIS; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 80052701432     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.3.158     Document Type: Article

References (31)

1. von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
2. Hellmann K. Anthracycline cardiac toxicity prevention by dexrazoxane: breakthrough of a barrier-sharpens antitumor profile and therapeutic index (Editorial). J Clin Oncol 1996; 14: 332-333.
3. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7: 141-146.
4. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992.
5. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I study. J Clin Oncol 1995; 13: 1777-1785.
6. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(suppl 4): 30-35.
7. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-149.
8. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006; 42: 882-887.
9. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711-716.
10. 2. Ann Oncol 2000; 8: 1029-1033.
11. Minisini AM, Andreetta C, Fasola G, Puglisi F. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev Anticancer Ther 2008; 8: 331-342.
12. O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003; 4: 318-328.
13. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999; 10: 1113-1116.
14. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, 1979.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
17. Slamon DL, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
18. Ranson MR, Cheeseman S, White S, Margison J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 2001; 37: 115-120.
19. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin vs vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893-3901.
20. Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989; 16(2 Suppl 4): 2-4.
21. Variol P, Nguyen L, Tranchand B, Puozzo C. A simultaneous oral/intravenous population pharmacokinetic model. Eur J Clin Pharmacol 2002; 58: 467-476.
22. Bugat R, Variol P, Roche H, Fumoleau P, Robinet G, Senac I. The effect of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 2002; 50: 285-290.
23. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12: 1375-1381.
24. Puozzo C, Gridelli C. Non-small cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics. Clin Lung Cancer 2004; 5: 237-242.
25. Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 2006; 58: 742-748.
26. Rimassa L, Carnaghi C, Garassino I. Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Trt 2003; 77: 185-188.
27. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age. Cancer Chemother Pharmacol 2008; 62: 285-292.
28. Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overex- pressing metastatic breast cancer. Clin Breast Cancer 2007; 7: 690-696.
29. Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32: 18-24.
30. Biganzoli L, Coleman R, Mnisini A, Hamilton A, Aapro M, Therasse P, et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (CaelyxTM) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007; 6l: 84-89.
31. O'Brien MER. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008; 19: 1-7.